Methods Mol Biol. 2021 Mar 27; doi: 10.1007/7651_2021_375. Epub 2021 Mar 27.

Efficient Generation of Functional Hepatocytes from Human Induced Pluripotent Stem Cells for Disease Modeling and Disease Gene Discovery.

Methods in molecular biology (Clifton, N.J.)

Satish Kumar, Joanne E Curran, Sarah Williams-Blangero, John Blangero

PMID: 33772461 DOI: 10.1007/7651_2021_375

Abstract

In vitro hepatocyte cell models are being used to study the pathogenesis of liver disease and in the discovery and preclinical stages of drug development. The culture of hepatic cell lines and primary hepatocytes as in vitro cell models has been carried out for several decades. However, hepatic cell lines (hepatic carcinoma generated or immortalized) have limited accuracy when recapitulating complex physiological functions of the liver. Additionally, primary hepatocytes sourced from human cadavers or medical biopsies are difficult to obtain due to sourcing limitations, particularly for large-scale population studies or in applications requiring large number of cells. Hepatocyte cultures differentiated from human embryonic stem cells (ESCs) and induced pluripotent stem cell (iPSCs) overcome in large part the limitations of traditional hepatocyte in vitro models. In this chapter, we described an efficient protocol routinely used in our laboratory to differentiate human iPSCs into functional hepatocyte cultures for in vitro modeling of liver function and disease. The protocol uses a three-stage differentiation strategy to generate functional hepatocytes from human iPSCs. The differentiated cells show characteristic hepatocyte morphology including flat and polygonal shape, distinct round nuclei, and presence of biliary canaliculi and they express hepatic markers alpha-fetoprotein (AFP), albumin (ALB), E-cadherin (CHD1), hepatocyte nuclear factor 4 alpha (HNF4α), and actin.

Keywords: Hepatocyte differentiation; Human; In vitro cell model; Induced pluripotent stem cell; Liver disease genetics; Liver toxicity and disease

References

1. Collins SD, Yuen G, Tu T, Budzinska MA, Spring K, Bryant K, Shackel NA (2019) In vitro models of the liver: disease modeling, drug discovery and clinical applications. In: JEE T-P (ed) Hepatocellular carcinoma. Codon Publications, Brisbane (AU). https://doi.org/10.15586/hepatocellularcarcinoma.2019.ch3 - PubMed
2. Astashkina A, Mann B, Grainger DW (2012) A critical evaluation of in vitro cell culture models for high-throughput drug screening and toxicity. Pharmacol Ther 134(1):82–106. https://doi.org/10.1016/j.pharmthera.2012.01.001 - PubMed
3. Zeilinger K, Freyer N, Damm G, Seehofer D, Knospel F (2016) Cell sources for in vitro human liver cell culture models. Exp Biol Med (Maywood) 241(15):1684–1698. https://doi.org/10.1177/1535370216657448 - PubMed
4. Underhill GH, Khetani SR (2018) Bioengineered liver models for drug testing and cell differentiation studies. Cell Mol Gastroenterol Hepatol 5(3):426–439.e421. https://doi.org/10.1016/j.jcmgh.2017.11.012 - PubMed
5. Godoy P, Hewitt NJ, Albrecht U, Andersen ME, Ansari N, Bhattacharya S, Bode JG, Bolleyn J, Borner C, Bottger J, Braeuning A, Budinsky RA, Burkhardt B, Cameron NR, Camussi G, Cho CS, Choi YJ, Craig Rowlands J, Dahmen U, Damm G, Dirsch O, Donato MT, Dong J, Dooley S, Drasdo D, Eakins R, Ferreira KS, Fonsato V, Fraczek J, Gebhardt R, Gibson A, Glanemann M, Goldring CE, Gomez-Lechon MJ, Groothuis GM, Gustavsson L, Guyot C, Hallifax D, Hammad S, Hayward A, Haussinger D, Hellerbrand C, Hewitt P, Hoehme S, Holzhutter HG, Houston JB, Hrach J, Ito K, Jaeschke H, Keitel V, Kelm JM, Kevin Park B, Kordes C, Kullak-Ublick GA, LeCluyse EL, Lu P, Luebke-Wheeler J, Lutz A, Maltman DJ, Matz-Soja M, McMullen P, Merfort I, Messner S, Meyer C, Mwinyi J, Naisbitt DJ, Nussler AK, Olinga P, Pampaloni F, Pi J, Pluta L, Przyborski SA, Ramachandran A, Rogiers V, Rowe C, Schelcher C, Schmich K, Schwarz M, Singh B, Stelzer EH, Stieger B, Stober R, Sugiyama Y, Tetta C, Thasler WE, Vanhaecke T, Vinken M, Weiss TS, Widera A, Woods CG, Xu JJ, Yarborough KM, Hengstler JG (2013) Recent advances in 2D and 3D in vitro systems using primary hepatocytes, alternative hepatocyte sources and non-parenchymal liver cells and their use in investigating mechanisms of hepatotoxicity, cell signaling and ADME. Arch Toxicol 87(8):1315–1530. https://doi.org/10.1007/s00204-013-1078-5 - PubMed
6. Donato MT, Lahoz A, Castell JV, Gomez-Lechon MJ (2008) Cell lines: a tool for in vitro drug metabolism studies. Curr Drug Metab 9(1):1–11. https://doi.org/10.2174/138920008783331086 - PubMed
7. Antherieu S, Rogue A, Fromenty B, Guillouzo A, Robin MA (2011) Induction of vesicular steatosis by amiodarone and tetracycline is associated with up-regulation of lipogenic genes in HepaRG cells. Hepatology 53(6):1895–1905. https://doi.org/10.1002/hep.24290 - PubMed
8. Sharanek A, Burban A, Burbank M, Le Guevel R, Li R, Guillouzo A, Guguen-Guillouzo C (2016) Rho-kinase/myosin light chain kinase pathway plays a key role in the impairment of bile canaliculi dynamics induced by cholestatic drugs. Sci Rep 6:24709. https://doi.org/10.1038/srep24709 - PubMed
9. Pan C, Kumar C, Bohl S, Klingmueller U, Mann M (2009) Comparative proteomic phenotyping of cell lines and primary cells to assess preservation of cell type-specific functions. Mol Cell Proteomics 8(3):443–450. https://doi.org/10.1074/mcp.M800258-MCP200 - PubMed
10. Ramboer E, Vanhaecke T, Rogiers V, Vinken M (2015) Immortalized human hepatic cell lines for in vitro testing and research purposes. Methods Mol Biol 1250:53–76. https://doi.org/10.1007/978-1-4939-2074-7_4 - PubMed
11. Lin C, Khetani SR (2016) Advances in engineered liver models for investigating drug-induced liver injury. Biomed Res Int 2016:1829148. https://doi.org/10.1155/2016/1829148 - PubMed
12. Kumar S, Blangero J, Curran JE (2018) Induced pluripotent stem cells in disease modeling and gene identification. Methods Mol Biol 1706:17–38. https://doi.org/10.1007/978-1-4939-7471-9_2 - PubMed
13. Kumar S, Blackburn NB, Leandro AC, Leandro M, Peralta JM, Blangero J, Curran JE (2019) Human iPSC-derived hepatocytes reveal the functional consequences of an hispanic rare sequence variant in the DEGS1 gene. In: Abstracts of the University of Texas Rio Grande Valley, School of Medicine 3rd annual research symposium, McAllen Convention Center, 13–14 September, 2019 - PubMed
14. Nwosuocha D, DeLeon E, Leandro AC, Leandro M, Peralta JM, Blangero J, Curran JE, Kumar S (2019) Functional and transcriptomic profiles of iPSC generated mature hepatocytes. In: Abstracts of the University of Texas Rio Grande Valley, School of Medicine 3rd annual research symposium, McAllen Convention Center, 13–14 September, 2019 - PubMed
15. Ma X, Duan Y, Tschudy-Seney B, Roll G, Behbahan IS, Ahuja TP, Tolstikov V, Wang C, McGee J, Khoobyari S, Nolta JA, Willenbring H, Zern MA (2013) Highly efficient differentiation of functional hepatocytes from human induced pluripotent stem cells. Stem Cells Transl Med 2(6):409–419. https://doi.org/10.5966/sctm.2012-0160 - PubMed
16. Magner NL, Jung Y, Wu J, Nolta JA, Zern MA, Zhou P (2013) Insulin and IGFs enhance hepatocyte differentiation from human embryonic stem cells via the PI3K/AKT pathway. Stem Cells 31(10):2095–2103. https://doi.org/10.1002/stem.1478 - PubMed
17. Kumar S, Curran JE, Espinosa EC, Glahn DC, Blangero J (2020) Highly efficient induced pluripotent stem cell reprogramming of cryopreserved lymphoblastoid cell lines. J Biol Methods 7(1):e124. https://doi.org/10.14440/jbm.2020.296 - PubMed
18. Kumar S, Curran JE, Glahn DC, Blangero J (2016) Utility of lymphoblastoid cell lines for induced pluripotent stem cell generation. Stem Cells Int 2016:2349261. https://doi.org/10.1155/2016/2349261 - PubMed

Publication Types

• Journal Article